Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Grazoprevir

Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively[1][2]. Grazoprevir inhibits SARS-CoV-2 3CLpro activity[3].

Product Specifications

CAS Number

1350514-68-9

Product Name Alternative

MK-5172

UNSPSC

12352005

Hazard Statement

H303, H320

Target

HCV; HCV Protease; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/MK-5172.html

Purity

99.94

Solubility

DMSO : 50 mg/mL (ultrasonic) |Ethanol : 66.67 mg/mL (ultrasonic)

Smiles

COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC4=O)C(O[C@H]5CN(C([C@H](C(C)(C)C)N4)=O)[C@H](C(N[C@@]([C@@H]6C=C)(C6)C(NS(C7CC7)(=O)=O)=O)=O)C5)=N2)C=C1

Molecular Formula

C38H50N6O9S

Molecular Weight

766.90

Precautions

H303, H320

References & Citations

[1]Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56 (8) :4161-7.|[2]Harper S, et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med Chem Lett. 2012 Mar 2;3 (4) :332-6.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Antivir Res. 2019 Nov;171:104612.|Antiviral Res. 2017 Mar;139:18-24. |Antiviral Res. 2022 Jan:197:105224.|bioRxiv. 2023 Feb 27:2023.02.27.530290.|bioRxiv. 2023 Oct 26:2023.10.26.561921.|bioRxiv. 2024 Dec 3:2024.11.26.625483.|bioRxiv. 2024 Mar 12.|Cancer Cell. 2022 Nov 14;40 (11) :1294-1305.e4.|Cancer Immunol Res. 2021 Sep;9 (9) :999-1007.|Development. 2025 May 16:dev.204505.|Elife. 2020 Jun 9:9:e56469.|J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15:1110-1111:15-24.|J Gastroenterol. 2019 May;54 (5) :449-458. |J Pharm Biomed Anal. 2020 Jan 30;178:112964.|Nat Biotechnol. 2019 Oct;37 (10) :1209-1216.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Nat Methods. 2018 Jul;15 (7) :519-522.|Patent. US12065501.|Patent. US20180346589A1.|Patent. US20190010245A1.|Patent. US20220025003A1.|Pharmaceuticals (Basel) . 2022 Feb 18;15 (2) :242.|Research Square Preprint. 2024 Jan 23.|Sci Rep. 2022 Jul 16;12 (1) :12197.|Sci Rep. 2019 Apr 5;9 (1) :5722.|Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|University of Glasgow. 2024 Mar.|Cancer Cell. 2022 Nov 14;40 (11) :1294-1305.e4.|Cancer Cell. 2024 Nov 11;42 (11) :1955-1969.e7.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

trans-4-Hydroxycyclohexylcarboxylic Acid
TRC-H826900-500MG 500 mg

trans-4-Hydroxycyclohexylcarboxylic Acid

Sign In for Pricing
View Details
soxA Goat Polyclonal Antibody
TA396684S 25 µL

soxA Goat Polyclonal Antibody

Sign In for Pricing
View Details
Alox12 Mouse Gene Knockout Kit (CRISPR)
KN501155 1 Kit

Alox12 Mouse Gene Knockout Kit (CRISPR)

Sign In for Pricing
View Details
AY358078 Mouse Gene Knockout Kit (CRISPR)
KN501896 1 Kit

AY358078 Mouse Gene Knockout Kit (CRISPR)

Sign In for Pricing
View Details
CD62L (L-Selectin) (CD62L/1588), CF594 conjugate, 0.1mg/mL
BNC941588-500 1x 500 µL

CD62L (L-Selectin) (CD62L/1588), CF594 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
N-Vanillylnonanamide-d3
TRC-V097637-1MG 1 mg

N-Vanillylnonanamide-d3

Sign In for Pricing
View Details